Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]
Discontinued
Reference number: GID-TA10363
Following an update from Daiichi Sankyo UK, the committee date for the appraisal of quizartinib for treating relapsed or refractory acute myeloid leukaemia has been rescheduled to 2 October 2019.